Drugs / ALKS 3831
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02922426 | Sep 2016 → Jul 2017 | — | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02669758 | Jan 2016 → Jun 2018 | schizophrenia | Alkermes, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALKS 3831 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02922426 ↗ |
| Route | Oral | “Oral, bilayer tablet” NCT02922426 ↗ |